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Abstract
Background: Cholinergic projection from the septum to the hippocampus is crucial for normal cognitive function and
degeneration of cells and nerve fibers within the septohippocampal pathway contributes to the pathophysiology of
Alzheimer’s disease. Bone morphogenetic protein (BMP) 9 is a cholinergic differentiating factor during development both in
vivo and in vitro.
Methodology/Principal Findings: To determine whether BMP9 could protect the adult cholinergic septohippocampal
pathway from axotomy-evoked loss of the cholinergic phenotype, we performed unilateral fimbria-fornix transection in
mice and treated them with a continuous intracerebroventricular infusion of BMP9 for six days. The number of choline
acetyltransferase (CHAT)-positive cells was reduced by 50% in the medial septal nucleus ipsilateral to the lesion as
compared to the intact, contralateral side, and BMP9 infusion prevented this loss in a dose-dependent manner. Moreover,
BMP9 prevented most of the decline of hippocampal acetylcholine levels ipsilateral to the lesion, and markedly increased
CHAT, choline transporter CHT, NGF receptors p75 (NGFR-p75) and TrkA (NTRK1), and NGF protein content in both the
lesioned and unlesioned hippocampi. In addition, BMP9 infusion reduced bilaterally hippocampal levels of basic FGF (FGF2)
protein.
Conclusions/Significance: These data indicate that BMP9 administration can prevent lesion-evoked impairment of the
cholinergic septohippocampal neurons in adult mice and, by inducing NGF, establishes a trophic environment for these
cells.
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Introduction
The cholinergic neurons of the medial septal nucleus send their
axons to the hippocampus providing it with a robust modulatory
input mediated by their neurotransmitter, acetylcholine (ACh).
Although not numerous (approximately 3000 in the mouse) [1],
their significance includes critical functions in processes of
learning, memory, attention, and sleep [2,3]. Degeneration and/
or malfunction of the septohippocampal cholinergic system is
thought to contribute to cognitive decline of old age and to
memory loss characteristic of Alzheimer’s disease [4]. Lesions of
this pathway in laboratory animals impair learning and memory in
various tests [5]. Because these abnormalities are related to the
compromised cholinergic neurotransmission and since the septo-
hippocampal pathway is the main extrinsic source of ACh to the
hippocampus, multiple experimental strategies aimed at restoring
the content of this neurotransmitter in the hippocampus have been
tried. For example, grafts of ACh-producing cells ameliorated
some lesion-evoked cognitive deficits [6,7]. In an effort to correct
similar deficits in AD, a number of therapeutic approaches have
also been undertaken to increase the levels of brain ACh in
humans. Some of these strategies are based on the use of
acetylcholinesterase inhibitors, to reduce the rate of degradation of
ACh in brain [8]. Other approaches include the use of growth
factors known to be neurotrophic for cholinergic neurons and to
be effective in animal models – NGF being the best characterized
[9–17] –and clinical trials on NGF gene therapy in an attempt to
increase the functional state and survival of cholinergic neurons in
AD patients have been initiated [18].
We have previously shown that bone morphogenetic protein
(BMP) 9 is an inducer of the cholinergic phenotype of septal
neurons in culture and in embryonic brain in vivo and a
maintenance factor for these cells [19]. Moreover, in fetal septal
cell cultures, BMP9 induces the expression of multiple genes, a
large fraction of which belong to the transcriptome of the septal
cholinergic neurons [20], indicating that BMP signaling may
participate in the maturation of these cells more broadly, i.e.
beyond their neurotransmitter specification. Interestingly, several
BMP9-induced genes encode proteins with trophic activities for
cholinergic neurons, suggesting that BMP signaling helps to
generate a favorable milieu for these cells. Indeed, we have
recently demonstrated that some of the effects of BMP9 are
apparently mediated by autocrine action of NGF that is induced in
these neurons in response to BMP9 [21]. Multiple BMPs and their
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and modulate adult neurogenesis that is characteristic to this brain
region [22]. In the present study we found that intracerebroven-
tricular (ICV) infusion of BMP9 prevents the loss of cholinergic
neurons, as defined by their expression of the ACh-synthesizing
enzyme choline acetyltransferase (CHAT), in the septum following
unilateral fimbria-fornix transection in mice and upregulates the
expression of hippocampal NGF and its receptors NGFR-p75 and
TRKA (NTRK1).
Results
BMP9 prevents lesion-evoked loss of choline
acetyltransferase (CHAT) positive medial septum neurons
To assess the in vivo activity of BMP9 on injured adult septal
cholinergic neurons, we performed unilateral fimbria-fornix
transections in mice and treated them with varying doses of
BMP9 administered via continuous ICV infusion over a 6-day
period. Immunohistochemical staining of the septum with an
antibody for CHAT was then used to determine the effects of the
lesion and of BMP9. Serial images of the septal/diagonal band area
from CHAT-immunostained histological sections were processed
for cell number quantification within the region of interest (ROI)
encompassing the individual left and right medial septal nuclei
defined by triangular shapes shown in Figure 1 as described in the
methods. The ROI were analyzed for cell number in at least three
non-consecutive sections per animal. As expected, multiple CHAT-
immunoreactive cells within the medial septum and the diagonal
band were observed. Mice subjected to the fimbria-fornix
transection and infused with PBS alone, were characterized by a
50% loss in the number of the CHAT-positive cells in the medial
septum ipsilateral to the lesion (Fig. 2 and 3). Sparing of the
cholinergicneuronswasevident withincreasingdosesofBMP9,and
there was little or no loss of these neurons in animals receiving 15
and 38 ng/h of BMP9 (Figs. 2 and 3), indicating that BMP9 was
highly effective in preventing the loss of CHAT-positive neurons
whose axons had been transected. The dose-dependent and
saturable action of BMP9 could be described by a rectangular
hyperbola with a good fit (R
2=0.89) and permitted the estimation
of the EC50 value for BMP9 at 1 ng/h (Fig. 3).
BMP9 attenuates lesion-evoked reduction of
acetylcholine levels in the hippocampus
To determine whether BMP9 could affect ACh levels in the
hippocampus, we performed similar experiments in mice with
fimbria-fornix transections using a small, yet close to a fully
effective dose of BMP9 identified above (8 ng/h, via a 6-day ICV
infusion; Fig. 3), and measured ACh content in both lesioned and
unlesioned hippocampi. Seven days after the lesion, ACh content
in the hippocampus ipsilateral to the lesion was reduced to 34%
compared to the unlesioned side in mice that had been infused
with PBS, whereas ACh levels in the hippocampus ipsilateral to
the lesion in mice infused with BMP9 were reduced to only 72%
(Fig. 4). Thus, BMP9 treatment significantly (p,0.01) prevented
the reduction in ACh levels in the lesioned hippocampus when
compared to untreated animals. The magnitude of this effect was
the same regardless of whether ACh content was expressed per
hippocampus, or per mg of protein.
BMP9 increases cholinergic marker expression in the
hippocampus
To determine whether cholinergic cell marker expression was
modulated in the hippocampus of BMP9 treated mice with
fimbria-fornix lesions, we used immunoblotting to measure protein
levels of CHAT and choline transporter CHT (a protein that
catalyzes the uptake of choline used for ACh synthesis in
cholinergic neurons). CHAT protein levels were reduced with
the lesion in both BMP9-treated and untreated mice (Fig. 5).
BMP9 increased CHAT levels in both lesioned and unlesioned
hippocampi. However, these levels were only significantly
(p,0.05) different in the unlesioned hippocampus. Two-way
ANOVA revealed a statistically significant effect of the lesion
(p=0.002) and of BMP9 (p=0.01). The post hoc test revealed that
Figure 1. Sections of mouse brain showing a representative
image of the unilateral transection of fimbria-fornix (top
panel) and the ROI stained with an anti-CHAT antibody
(Bottom Panel). CHAT-positive cells are seen in the medial septum,
the diagonal band and in the striatum (bottom panel). The lines show
the ROI used for cell count analysis in the medial septum. The ROI was
defined by a triangular shape that extended, dorso-ventrally, from the
apex of the medial septum (A) to an imaginary line connecting the
lower limits of the anterior commissures on each hemisphere (B) and,
medio-laterally, from the midline (A) to the outer limits of the medial
septal area (C and D).
doi:10.1371/journal.pone.0021166.g001
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lesioned side was close to statistical significance (p=0.054) and
that BMP9 increased CHAT levels on the intact side (p=0.02).
Note, that the comparison of the hippocampal CHAT levels
between the control animals (PBS-infused unlesioned side) and the
BMP9-infused lesioned side showed no significant difference
(p=0.54) indicating that the BMP9 treatment tended to cause
normalization of the CHAT protein levels. CHT protein levels
were elevated in the hippocampus of BMP9 treated mice
compared to PBS-infused controls, but only those in the lesioned
side were statistically different from controls (p,0.05; Fig. 5).
BMP9 increases NGF and NGF-receptors levels in the
hippocampus
It is well established that basal forebrain cholinergic neurons
benefit from hippocampal NGF as a trophic factor for survival and
maintenance of their cholinergic phenotype [9–12]. We have
recently shown that BMP9 can induce NGF as an autocrine/
paracrine cholinergic trophic factor in developing basal forebrain
neurons [21]. To determine whether BMP9 had an effect on NGF
content in the hippocampus of fimbria-fornix lesioned mice and,
perhaps, explain some of our data described above, we analyzed
the levels of NGF protein in the hippocampus of these mice by
ELISA. NGF levels were increased in the hippocampus of BMP9
treated mice by 47% and 61% on the lesioned and unlesioned
side, respectively, compared to the corresponding levels in the
hippocampus of PBS infused control animals (Fig. 6).
To determine whether BMP9 had an effect on NGF receptors
levels, we measured NGFR-p75 and TRKA (NTRK1) by Western
Figure 2. Representative photomicrographs of anti-CHAT antibody stained basal forebrain areas of mice with a unilateral
septohippocampal lesion (right side of the images) following six days of constant intracerebroventricular infusion of vehicle (no
BMP9) or BMP9 at doses indicated. Note a dramatic reduction of the number of CHAT-positive cells in the control brain and sparing of these
neurons when BMP9 was administered.
doi:10.1371/journal.pone.0021166.g002
Figure 3. BMP9 protects medial septum cholinergic neurons
from axotomy-evoked degeneration. CHAT-positive cells were
counted as shown in Fig. 1 on both sides of the medial septum and the
average cell number on the lesioned side is expressed as % of the
average cell number on the intact side. See Fig. 2 for representative
sections. Using the best fit to a rectangular hyperbola (R
2=0.89) the
EC50 value for BMP9 was 1 ng/h. Note, at 15 ng/h and 38 ng/h BMP9
prevented all loss of CHAT-positive neurons.
doi:10.1371/journal.pone.0021166.g003
Figure 4. Acetylcholine content in hippocampus measured by
HPLC in mice with a unilateral septohippocampal lesion
following seven days of constant intracerebroventricular
infusion of vehicle or 8 ng/h of BMP9. Note a significant
(*p,0.01; 72%) sparing of the loss of hippocampal ACh content in
lesioned mice receiving BMP9.
doi:10.1371/journal.pone.0021166.g004
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higher in the hippocampus of lesioned and unlesioned BMP9
treated mice, respectively, compared to PBS-infused animals
Figure 5. Protein levels of cholinergic markers in hippocampus
(HPP). CHAT and CHT were measured by Western blot (top panel;
representative blot images) in hippocampi from lesioned and
unlesioned side, the intensities of the immunoreactive bands were
quantified, normalized to those of beta actin and the data are
expressed as % of the values from PBS-infused mice on the unlesioned
side. Two-way ANOVA of these data for CHAT revealed a statistically
significant effect of the lesion (p=0.002) and of BMP9 (p=0.01). The
post hoc test revealed that the reduction of the CHAT levels in the PBS-
treated mice on the lesioned side was close to statistical significance
(p=0.054) and that BMP9 increased CHAT levels on the intact side
(p=0.02). Note, that the comparison of the hippocampal CHAT levels
between the control animals (PBS-infused unlesioned side) and the
BMP9-infused lesioned side showed no significant difference (p=0.54)
indicating that the BMP9 treatment tended to cause normalization of
the CHAT protein levels. (* p,0.05 vs. PBS; # p,0.05, vs. lesioned
BMP9-treated). Two-way ANOVA of the data for CHT revealed an effect
of BMP9 (p,0.02); (* p,0.02 BMP9 vs PBS on the lesioned side).
doi:10.1371/journal.pone.0021166.g005
Figure 6. NGFR-p75, TrkA and NGF protein levels in hippo-
campus (HPP). Mice were treated as in Fig. 4. NGFR-p75 (** p,0.01
BMP vs PBS on the same side) and TrkA (significant treatment effect of
BMP9 by two-way ANOVA, p,0.05) were measured by Western blot
(top panel) and the data quantified as in Fig. 5. NGF was measured by
ELISA (* p,0.05, ** p,0.01 BMP9 vs PBS on the same side).
doi:10.1371/journal.pone.0021166.g006
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and unlesioned hippocampi (overall significant treatment effect,
p,0.05, by two-way ANOVA; Fig. 6).
BMP9 decreases basic-FGF content in the hippocampus
The interaction between BMP and other growth factors
promoting progenitor cell proliferation, such as basic FGF
(FGF2), is essential during brain development and it may also be
important in cell repair following brain injury. To determine
whether BMP9 affects FGF2 content in the hippocampus, we
measured the levels of this growth factor by ELISA. BMP9
significantly reduced FGF2 levels in both lesioned and unlesioned
hippocampi (p,0.05), whereas the levels of this growth factor were
not significantly different in vehicle treated mice regardless of the
lesion (Fig. 7).
Discussion
These data show that BMP9 administered at the time of a septo-
hippocampal transection prevents the loss of septal cholinergic
neurons (i.e. CHAT-immunopositive cells) normally observed with
this type of injury. They also show that BMP9 partially prevents
the loss of ACh and other cholinergic markers in the lesioned
hippocampus, and that BMP9 induces hippocampal NGF that
could in part be responsible in mediating the above effects.
Unilateral fimbria-fornix transection has been one of the most
successful models in the study of the effects of growth factors on
injured septal cholinergic neurons. Following this procedure, the
ipsilateral septal neurons show downregulated expression of
CHAT [13–17] and of another cholinergic marker the vesicular
ACh transporter [23]. It is generally thought that following fimbria
fornix axotomy the cholinergic septal neurons tend not to
degenerate and die [24,25], instead, devoid of contact with their
targets these neurons lose their cholinergic phenotype without
dying [12]. Whether the actions of BMP9 observed here result
from a direct effect of BMP9 on the cholinergic neurons subjected
to the lesion, or indirectly mediated by other factors, or both,
remains uncertain. It has been shown that, following-fimbria
fornix transection, NGF can rescue septal neurons from the loss of
their cholinergic phenotype when administered at the time of the
lesion [14], as is the case for BMP9 in the present study. Thus, our
data from this and previous studies [21] suggest that BMP9 bears
similarity to the actions of NGF in a variety of ways including
increased ACh production and CHAT expression. As noted above
we found that BMP9 can induce the synthesis and release of NGF
in septal cultures, and that NGF can partially mediate some of the
effects of BMP9 [21]. Moreover, like NGF, BMP9 can increase
gene expression of NGF receptor NGFR-p75 [21,26]. NGFR-p75
would be expected to potentiate NGF signaling via the NGF
signaling receptor, TrkA [27] whose hippocampal expression is
also increased in BMP9-infused mice. Thus, in theory, BMP9 by
increasing both NGF protein synthesis and, concurrently,
upregulating NGF receptor (NGFR-p75 and TrkA) expression in
septal neurons, could rescue their cholinergic phenotype upon
delayed administration following fimbria-fornix lesions. Although
we did not explore this possibility, this could have direct
translational implications in the search for treatments of disease
states affecting basal forebrain cholinergic neurons with dysfunc-
tion of NGF and its receptors, such as Alzheimer’s disease [4,28].
BMP signaling plays an important role in both neurogenesis and
gliogenesis [29]. The interaction between BMP and other growth
factors, such as FGF2, is central in the maturation of the nervous
system [30] and could also, play a significant role during neuronal
cell repair following brain injury. We found that BMP9
significantly reduced FGF2 levels in both lesioned and unlesioned
hippocampi, whereas the levels of this growth factor remained
unchanged in vehicle treated mice regardless of the lesion. FGF2
promotes the proliferation of progenitor cells, preventing their exit
from the cell cycle [31]. BMPs, in contrast, tend to reduce cell
proliferation, promoting cell differentiation and cell lineage
restriction. During development, these apparently opposing effects
may contribute to a specific cell fate [32]. Our data suggest that,
following fimbria-fornix transection, BMP9 may indirectly support
and maintain the cholinergic phenotype by an alternative
mechanism, namely, by reducing FGF levels and maintaining
the state of cholinergic differentiation.
In spite of an apparently complete, microscopically verified,
transection of fimbria fornix, detectable levels of ACh still persisted
6-days post-lesion in the hippocampus, albeit drastically reduced,
and treatment with BMP9 partially blocked this loss of
hippocampal ACh content. The most likely explanation for this
is apparent upregulation of ACh synthesis and/or sprouting of the
nerve terminals of the septal cholinergic neurons that project to
the hippocampus using the supracallosal pathway [33–35] and a
ventral pathway (ansa lenticularis) [36,37]. In addition, early
studies have pointed out the possible presence of intrinsic
cholinergic neurons in the hippocampus [38–40] and we [41]
and others [42] have observed CHT-immunoreactive cells in the
rat hilus. Note that in the current study we found a significant
increase in CHT protein content evoked by BMP9 in the lesioned
hippocampus, but not the unlesioned side. CHT is responsible for
the high affinity transport of choline into synaptic nerve terminals
and can be the rate limiting step in ACh synthesis [3]. Previous
mouse model studies (e.g. CHAT haploinsufficiency [40]) have
shown that upregulation of CHT expression can provide
functional compensation in states of cholinergic dysfunction [43].
In our lesion experiments, the loss of septohippocampal input to
the lesioned hippocampus could render intrahippocampal cholin-
ergic neurons more susceptible to BMP9, and upregulate CHT
protein content to compensate for the loss of extrinsic cholinergic
innervation. In addition, our results show that BMP9 significantly
increased CHAT protein content in the unlesioned hippocampi
indicating that it increases CHAT expression in adult basal
forebrain cholinergic neurons as it does during development [19].
In the lesioned hippocampi treated with BMP9 CHAT protein
levels were not statistically different than those in PBS-treated
intact and lesioned controls, suggesting that BMP9 treatment
Figure 7. FGF2 protein levels in hippocampus (HPP). Mice were
treated as in Fig. 4. FGF2 was measured by ELISA (* p,0.05 BMP9 vs PBS
on the same side).
doi:10.1371/journal.pone.0021166.g007
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CHAT.
In conclusion our data show that intracerebral administration of
BMP9 protects the axotomized septal cholinergic neurons from
the loss of their neurotransmitter phenotype and increases
hippocampal expression of NGF, a critical growth factor for these
neurons. Together the results indicate that BMP9 may be further
explored as a therapeutic factor for these neurons in conditions
characterized by their malfunction.
Materials and Methods
Animals and Procedures
CD-1 male mice (5 animals per group in each experiment) were
used between 40 and 60 days of age. Mice were deeply
anesthetized (i.p.) with a mixture of ketamine (90 mg/kg) and
xylazine (8 mg/kg) and administered a single injection of
prophylactic antibiotic therapy (Ampicillin, 30 mg/kg, i.p.). Their
heads were shaved, and the mice were placed in a stereotaxic
apparatus. All interventions were performed aseptically on a sterile
field (3 M Steri-Drape, C#: 1021). A midsagittal incision (1 cm
length) was performed on the scalp, and a subcutaneous tunnel
was opened between the shoulder blades, where the pumps were
implanted. The periosteum on the surface of the skull was
removed by gently rubbing with a sterile Q-tip. Once the bregma
had been identified, the tip of the ICV cannula device held in the
stereotaxic apparatus was positioned at coordinates bregma
20.5 mm, right-lateral 1 mm. A hole was then opened in the
skull (1 mm diameter) and the cannula device was lowered and
fixed in place with Loctite-454 adhesive. The tip of the cannula
was located in the right lateral ventricle at a depth of 2 mm from
the surface of the skull. In addition, for the fimbria-fornix
transection, a coronal 2 mm wide slot was opened in the skull
on the contra lateral side, and the tip of a 2 mm wide blade was
inserted at coordinates: bregma 20.4 mm; left-lateral 0.3 mm;
depth 4.0 mm and subsequently removed. At the end of the
operation, the incision was closed with silk sutures and the animals
were left to recover from the anesthesia and monitored, before
they were placed back into their cages. In general, mice were
treated with an analgesic (Buprenex), recovered quickly, and were
actively feeding within the first 12 hours after the procedure. To
determine a dose-response curve to BMP9 (human recombinant,
Wyeth Research), mice were implanted with ICV cannulae (Brain
Kit #2; Durect Inc.) and osmotic pumps (1007D Alzet pumps;
Durect, Inc.), containing 100 ml of 1.6, 16, 32 or 76 ng/ml BMP9,
or vehicle (PBS, pH 7.4), and euthanized 6 or 7 days after. The
pumping rate was 0.5 ml/h; hence, mice treated with the BMP
received 0.8, 8, 16 or 38 ng/h of BMP9, respectively. Once an
effective concentration of BMP9 had been established, similar
experiments were performed, in which half of the animals received
BMP9 at a single concentration of 16 ng/ml (8 ng/h) for 6 days,
and half received vehicle. At the time of euthanasia, the pumps
were removed and inspected to assure that they had worked
properly, and the brains were dissected and fixed for immunohis-
tochemistry, or processed for other assays. All experiments with
animals were approved by the Boston University Institutional
Animal Care and Use Committee.
Immunohistochemistry and cell count
Brains were fixed in 20 volumes of PLP fixative (4%
paraformaldehyde, 75 mM lysine, 10 mM sodium periodate;
pH 7.4) for 1–2 h; they were transferred in fixative to refrigerator
(4–8uC) overnight, then cryoprotected in a graded series of 10%
and 20% glycerol/2% dimethylsulfoxide, in 0.1 M PBS, pH 7.3
(24 h each). Brains were maintained at 4uC until sectioning. Serial,
frozen sections (50 mm, coronal) were cut with a sliding microtome
from the anterior frontal pole of to the caudal occipital region.
Sections were maintained in PBS/sodium azide in 6-well trays
until analysis. For CHAT immunohistochemistry, sections were
transferred to Tris-buffered salt solution, containing Tween-20
(TBS-T) and 10% rabbit serum for 1 h at room temperature.
Following blocking of sections in serum, they were incubated
overnight at room temperature with primary anti-CHAT antibody
(Millipore AB144P; 1:200) and 2% rabbit serum in TBS-T
solution. Sections were then washed, blocked with 2% rabbit
serum for 1 h, and incubated for 2 h with secondary antibody
(Chemicon AQ106P; 1:1000) in 2% rabbit serum-containing TBS-
T. After washing sections in TBS-T, they were transferred to a
developing solution containing diaminobenzidine (DAB), sodium
imidazole, and hydrogen peroxide. To stop the reaction, sections
were then transferred to PBS, mounted on subbed slides and
coverslips sealed with Permount.
Brain sections were analyzed on an Olympus B061 microscope
(26 and 46 magnification objectives) connected to a megapixel
firewire high resolution camera (PixeLink). Serial images, 3 to 4
non-consecutive 100–300 mm apart, from the septal/diagonal
band area (region of interest, or ROI) were processed through
PixeLink software, stored in a computer, and analyzed with
ImageJ software (NIH) and an image-based tool for counting
nuclei (Center for Bio-image Informatics, UC Santa Barbara). The
ROI was defined by a triangular shape (Fig. 1) that extended,
dorso-ventrally, from the apex of the medial septum to an
imaginary line connecting the lower limits of the anterior
commissures on each hemisphere (Fig. 1, A) and, medio-laterally,
from the midline (Fig. 1, D) to the outer limits of the medial septal
area (Fig. 1, B and C). The data were analyzed by ANOVA and
regression analyses.
Acetylcholine content analysis
Hippocampi were dissected and collected in methanol, with 1 N
formic acid (10:1 v/v), and immediately homogenized. ACh was
extracted from the methanol extract in chloroform and water
(1:2:1 v/v). The aqueous phase was collected, dried under a
vacuum, and reconstituted in water. The content of ACh was
determined by HPLC with an enzymatic reactor containing
acetylcholinesterase and choline oxidase in series with an
electrochemical detector (Bioanalytical Systems, Inc.) based on
the method of Potter [44].
NGF and FGF-2 ELISA
Whole tissue extracts were prepared by adding lysis buffer
(50 mM Tris pH 7.5, 150 mM NaCl, 1% Nonidet NP-40, 10%
glycerol, 2 mM 4-(2-aminoethyl)- benzenesulfonyl fluoride, 1 mg/
ml leupeptin, 2 mg/ml aprotinin, 2 mg/ml pepstatin), followed by
gentle sonication, incubation on ice for 15 min, and a brief
centrifugation to clear. The supernatant from each sample was
diluted 4 times with Dulbecco’s PBS and acidified to pH 2.6. After
15 min of incubation at room temperature, the diluted superna-
tants were neutralized to pH 7.6, aliquoted and frozen for
subsequent measurement of NGF and FGF-2 (basic FGF) using
ELISA.
The EmaxH immunoassay systems (Promega) were used to
measure NGF in the samples. Flat-bottom 96 well plates (NUNC)
were first coated with solution containing a polyclonal antibody
against NGF (the first primary antibody solution) prepared in
carbonate coating buffer (100 mL/well, 1:1000 dilution) and
incubated for 16 h at 4uC. Following a wash in TBST (Tris-
buffered saline solution containing Tween 20), the coated wells
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temperature and washed again with TBST. Standard control
samples for NGF were diluted serially (1:2) from 250–0 pg/mL
and plated in duplicate (100 mL/well). The frozen ELISA samples
(described above) were thawed on ice, and every sample plated in
duplicate for measurement of NGF. Following a 6 h incubation
at room temperature, wells were washed in TBST. Diluted
monoclonal antibody against NGF (the second primary antibody
solution; 1:4000) was added to each well and incubated overnight
at 4uC. The wells were washed in TBST, incubated with a
secondary antibody conjugated to peroxidase for 2.5 h, washed
again in TBST, and treated with tetramethyl benzidine (TMB)
substrate for 10 min. The chromogen reaction was stopped by
adding 100 mL of 1 N hydrochloric acid.
The QuantikineH sandwich ELISA kit (R&D Systems) was used
to assay FGF-2 levels in the samples. ELISAs were performed
according to manufacture’s instructions. Briefly, microplates were
pre-coated with the first primary antibody (FGF-2 monoclonal).
Assay diluents were added to each well of the microplate (100 mL/
well). Standard control samples for FGF were diluted serially (1:2)
from 32–0 pg/ml with its respective calibrator diluent and plated
to two columns of wells (100 mL/well) designated for standard
curve in every plate. The frozen ELISA samples (described above)
were thawed on ice, and every sample plated in duplicate for
measurement of each of the factors. Following a 2-h incubation at
room temperature, wells were rinsed in wash buffer and treated
with an enzyme-linked second primary antibody solution for 2 h.
The second primary antibody was a monoclonal FGF-2 antibody
conjugated to alkaline phosphatase. The wells were rinsed in wash
buffer and a substrate solution was added to the wells and
incubated in the dark for 45 min for FGF-2. The color reaction
was stopped with 2N sulfuric acid.
The optical density of each well was measured using the Victor3
microplate reader (PerkinElmer Life Sciences). The intensity of
color was measured at a wavelength of 450 nm for NGF and at
490 nm for FGF-2. In order to correct for optical imperfections in
the plate, readings at 540 nm were subtracted from readings at
450 and 490 nm for NGF and FGF, respectively. The standard
curve was used to assess the validity of the protocol and to
determine the relative concentrations of NGF. Values in all
samples were normalized per gram of tissue assayed, and the
average value for each sample was calculated separately before
determining the group means.
Western blot
For Western blot analysis, the lysates were prepared as
described in the ELISA methods; however, a portion of the lysate
was taken before dilution in Dulbecco’s PBS. The extracts were
normalized for total protein and subjected to SDS-PAGE. After
transfer of protein to an Immoblon P membrane (Millipore), the
membrane was blocked with 5% nonfat dry milk in 16 Tris-
buffered saline (TBS) containing 0.1% Tween 20 for 2 h and then
probed overnight with either anti-NGFR-p75 polyclonal antibody
(1:1000) (Adavanced Targeting Systems); anti-CHAT polyclonal
antibody (1:1000) (Millipore); anti-CHT polyclonal antibody
(1:1000) (Millipore); anti-TrkA polyclonal antibody (1:1000)
(Millipore) or anti-b-actin monoclonal A5441 antibody (1:5000)
(Sigma). The antibody/antigen complexes on the membranes
were detected using a peroxidase-conjugated secondary IgG
(1:2000) and visualized using the enhanced chemiluminescence
method (Western Lightning, Perkin Elmer) and a Kodak Image
Station 440. Digitized images of immunoblots were quantified
using Kodak ID software. Protein levels were normalized with b-
actin values.
Data analysis
The statistical analysis of changes in protein levels and ACh
content was determined by two-way ANOVA, as appropriate. All
post hoc analysis were done using Fisher’s least-significant-
difference (LSD) test, with p,0.05 deemed as significant. Specific
p values are noted in the figure legends. All error bars indicate the
SEM.
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